EVOlution: A Unique and Powerful Fragment Screening Platform

Evotec has implemented a unique and powerful fragment screening platform, EVOlution™, capable of identifying low molecular weight fragments in a biologically relevant environment using ultra sensitive biochemical screening and NMR technologies accessing a library of 30,000+ high quality fragments designed and selected by medicinal chemists.

Combining this fragment screening process with subsequent protein-ligand X-ray crystallography, Evotec’s EVOlution™ platform can rapidly identify novel small molecule fragment hits for various, often difficult biological targets in a very short period of time. Leveraging its expertise in medicinal chemistry in combination with its fragment optimisation technology, Evotec can then rapidly progress fragment programmes to identify novel lead structures and preclinical development candidates.

Evotec has already validated the EVOlution™ technology against a number of biologically relevant targets including kinases, proteases and protein-protein interactions for therapeutic applications including the central nervous system (CNS), oncology, inflammation, metabolic disease and cardiovascular diseases.